418 reports of this reaction
2.1% of all TOBRAMYCIN SULFATE reports
#12 most reported adverse reaction
CYSTIC FIBROSIS is the #12 most commonly reported adverse reaction for TOBRAMYCIN SULFATE, manufactured by Fresenius Kabi USA, LLC. There are 418 FDA adverse event reports linking TOBRAMYCIN SULFATE to CYSTIC FIBROSIS. This represents approximately 2.1% of all 20,334 adverse event reports for this drug.
Patients taking TOBRAMYCIN SULFATE who experience cystic fibrosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CYSTIC FIBROSIS is a less commonly reported adverse event for TOBRAMYCIN SULFATE, but still significant enough to appear in the safety profile.
In addition to cystic fibrosis, the following adverse reactions have been reported for TOBRAMYCIN SULFATE:
The following drugs have also been linked to cystic fibrosis in FDA adverse event reports:
CYSTIC FIBROSIS has been reported as an adverse event in 418 FDA reports for TOBRAMYCIN SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CYSTIC FIBROSIS accounts for approximately 2.1% of all adverse event reports for TOBRAMYCIN SULFATE, making it a notable side effect.
If you experience cystic fibrosis while taking TOBRAMYCIN SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.